Adma biologics, inc. (ADMA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
CASH FLOWS FROM OPERATING ACTIVITIES:
NET LOSS

-48,279

-65,743

-43,758

-19,515

-17,969

-16,813

-15,527

-7,301

-5,903

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

3,258

3,446

2,692

469

469

247

210

182

219

Noncash Interest Expense Related to Notes Payable

-

-

-

-

-

-

-

-

847

Loss on Sale of Inventory

-

-

-

-

-

-

-

-

1,934

Loss on disposal of fixed assets

-207

-122

-10

0

-

-

-

-

-0

Stock-based compensation

2,650

2,223

1,561

1,250

1,711

1,248

888

626

22

Asset impairment charge

-

-

845

0

-

-

-

-

-

Warrant liability

-

-

-

-

-67

74

-43

0

-

Amortization of debt discount

1,180

1,104

781

676

353

133

91

2

740

Loss on extinguishment of debt

-

-

-

-

-719

0

-

-

-

Loss on extinguishment of debt

-9,962

0

-1,021

0

-

-

-

-

-

Gain on transfer of plasma center assets

11,527

0

-

-

-

-

-

-

-

Amortization of deferred financing costs

-

-

-

-

39

125

99

2

0

Payment-in-kind interest

-

-

-

-

124

176

0

-

-

Non-cash interest expense related to notes payable

-

-

-

-

-

-

-

1

-

Loss on sale of equipment

-

-

-

-

-

-

-

-18

-

Amortization of license revenue

-142

-142

-142

-142

-127

-75

-44

0

-

Changes in operating assets and liabilities:
Accounts receivable

2,077

-2,487

2,862

93

540

383

-39

-39

0

Inventories

34,650

5,987

-589

1,574

1,737

39

403

118

-308

Prepaid expenses and other current assets

773

540

941

202

-32

-155

190

48

-5

Deposits and other assets

-107

208

482

0

-

14

-593

-115

-

Restricted Cash

-

-

-

-

-

-

-

-

-90

Accounts payable

3,274

-20

2,812

476

202

-937

1,608

-244

40

Accrued expenses

806

406

614

416

-199

1,351

76

150

284

Accrued interest

-

-

-

-

-

-69

-36

0

-

Deferred Revenue

-

-

-

-

1,525

0

1,700

0

-

Other current and non-current liabilities

-190

174

-11

-

-

-

-

-

-

Other current and non-current liabilities

-

-

-

-30

-

-

-

-

-

Deferred rent liability

-

-

-

-

45

-22

-22

-22

-22

Net cash used in operating activities

-76,193

-62,678

-37,271

-18,268

-15,418

-14,704

-10,887

-6,903

-1,431

CASH FLOWS FROM INVESTING ACTIVITIES:
Sales of short-term investments

-

-

5,390

16,657

16,414

-

-

-

-

Purchase of short-term investments

-

-

-

15,680

18,130

1,717

2,935

0

-

Purchase of property and equipment

3,811

2,095

2,676

73

26

2,323

196

118

0

Cash acquired in acquisition transaction

-

-

12,500

0

-

-

-

-

-

Net cash provided by (used in) investing activities

-3,811

-2,095

15,213

904

-1,741

-4,040

-3,131

-118

-0

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Hercules note payable, net of fees

-

-

-

-

-

9,850

1,000

3,906

0

Repurchase of common stock

-

-

-

-

-

-

-

150

0

Proceeds from Convertible Notes Payable

-

-

-

-

-

-

-

-

1,500

Principal payments on note payable

30,000

0

20,000

0

15,300

0

-

200

200

Payment of end of term fee

2,760

0

1,790

0

-

-

-

-

-

Payment of debt refinancing fees

6,499

0

-

-

-

-

-

-

-

Proceeds from issuance of related party note payable

-

-

15,000

0

-

-

-

-

-

Proceeds from issuance of note payable

72,500

0

30,000

4,000

-

-

-

-

-

Prepayment penalty of early extinguishment of note payable

-

-

-

-

229

0

-

-

-

Payment of debt issuance costs

1,679

0

1,650

47

228

30

-

25

-

Proceeds from Oxford note payable

-

-

-

-

16,000

0

-

-

-

Proceeds from issuance of common stock, net of offering expenses

48,397

42,944

39,199

12,900

10,257

0

27,030

17,287

0

Proceeds from the exercise of stock options

75

13

7

0

49

0

-

-

-

Payment of Hercules end of term fee

-

-

-

-

132

0

-

-

-

Debt issuance costs

-

-

-

-

-

-

0

-

0

Equity issuance costs

-

-

-

-

0

12

386

1,338

0

Payments on finance lease obligations

29

16

0

15

13

12

11

9

9

Payments of leasehold improvement loan

0

19

16

-

-

-

-

-

-

Net cash provided by financing activities

80,002

42,921

60,750

16,838

10,401

9,795

27,632

19,470

1,290

Net (decrease) increase in cash and cash equivalents

-2

-21,852

38,692

-526

-6,758

-8,950

13,613

12,447

-141

Cash paid for interest

-

-

-

-

1,326

785

382

1

15

Conversion of notes payable and accrued interest into common stock

-

-

-

-

-

-

-

262

-

Reclassification of equity issuance costs to additional paid-in capital

-

-

-

-

12

0

428

0

-

Accrued equity issuance costs

-

-

-

-

-

55

41

69

-

Warrants issued in connection with note payable

-

-

-

-

367

402

0

229

0

Conversion of notes payable and interest in private placement

-

-

-

-

-

-

-

-

0

End of term liability in connection with note payable

-

-

-

-

1,432

0

26

106

0

Elimination of warrant liability

-

-

-

-

408

-

186

0

-

Stock retained by stockholders of shell company

-

-

-

-

-

-

-

0

-

Preferred stock issued upon note payable and interest conversion

-

-

-

-

-

-

-

-

9,636

Equity issuance costs, accrued and not paid

-

-

-

-

-

-

-

-

421

Issuance of common stock through the cashless exercise of warrants

-

-

-

-

-

-

-

-

0

Stock issued to shell company

-

-

-

-

-

-

-

-

0